{
    "info": {
        "nct_id": "NCT04811560",
        "official_title": "A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia",
        "inclusion_criteria": "Phase 1:\n\n* Relapsed or refractory (R/R) acute leukemia and has exhausted, or is ineligible for, available therapeutic options\n* Participants greater than or equal (>=)12 and less than (<) 18 years of age are only eligible for the Phase 1 adolescent cohort\n* Acute leukemia harboring histone-lysine N-methyltransferase 2A (KMT2A), nucleophosmin 1 gene (NPM1) or nucleoporin 98 gene or nucleoporin 214 gene (NUP98 or NUP214) alterations\n\nPhase: 2\n\n* Participants greater than 18 years are eligible\n* Must have had an initial diagnosis of acute myeloid leukemia (AML) per the WHO 2022 classification criteria and have relapsed/refractory disease\n* AML harboring KMT2A-r (gene rearrangement/translocation) or NPM1 mutations only\n\nFor Both Phase 1 and 2:\n\n* Pretreatment clinical laboratory values meeting the following criteria: (a) Hematology: white blood cell (WBC) count less than or equal to (<=) 20*10^9/liter (L) and (b) renal function; Estimated or measured glomerular filtration rate greater than or equal to (>=) 50 milliliter per minute (mL/min) per four variable modified diet in renal disease (MDRD) equation\n* Eastern Cooperative Oncology Group (ECOG) performance status grade of 0, 1 or 2. Adolescent participants only: Performance status >=70 by Lansky scale (for participants less than [<]16 years of age) or >=70 Karnofsky scale (for participants >=16 years of age)\n* A female of childbearing potential must have a negative highly sensitive serum beta-human chorionic gonadotropin at screening and within 48 hours prior to the first dose of study treatment\n* Participant must agree to all protocol required contraception requirements and avoid sperm or egg donations or freezing for future reproductive use while on study and for 90 days (males) or 6 months (females) after the last dose of study treatment\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
        "exclusion_criteria": "* Acute promyelocytic leukemia, diagnosis of Down syndrome associated leukemia or juvenile myelomonocytic leukemia according to World Health Organization (WHO) 2016 criteria\n* Active central nervous system (CNS) disease\n* Prior solid organ transplantation\n* QTc according to Fridericia's formula (QTcF) for males >= 450 millisecond (msec) or for females >= 470 msec. Participants with a family history of Long QT syndrome are excluded\n* Exclusion criteria related to stem cell transplant: a. Received prior treatment with allogenic bone marrow or stem cell transplant <=3 months before the first dose of study treatment; b. Has evidence of graft versus host disease; c. Received donor lymphocyte infusion <=1 month before the first dose of study treatment; d. Requires immunosuppressant therapy (exception: daily doses <=10 milligrams (mg) prednisone or equivalent are allowed for adrenal replacement)\n* Prior cancer immunotherapy within 4 weeks prior to enrollment or blinatumomab within 2 weeks prior to enrollment. Additional prior cancer therapies must not be given within 4 weeks prior to enrollment or 5 half-lives of the agent (whichever is shorter)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "* Participant must agree to all protocol required contraception requirements and avoid sperm or egg donations or freezing for future reproductive use while on study and for 90 days (males) or 6 months (females) after the last dose of study treatment",
                "criterions": [
                    {
                        "exact_snippets": "Participant must agree to all protocol required contraception requirements",
                        "criterion": "contraception requirements",
                        "requirement": {
                            "requirement_type": "agreement",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "avoid sperm or egg donations or freezing for future reproductive use while on study and for 90 days (males) or 6 months (females) after the last dose of study treatment",
                        "criterion": "sperm or egg donation or freezing for future reproductive use",
                        "requirement": {
                            "requirement_type": "avoidance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "avoid sperm or egg donations or freezing for future reproductive use while on study and for 90 days (males) or 6 months (females) after the last dose of study treatment",
                        "criterion": "sperm or egg donation or freezing for future reproductive use",
                        "requirement": {
                            "requirement_type": "duration (males)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 90,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "avoid sperm or egg donations or freezing for future reproductive use while on study and for 90 days (males) or 6 months (females) after the last dose of study treatment",
                        "criterion": "sperm or egg donation or freezing for future reproductive use",
                        "requirement": {
                            "requirement_type": "duration (females)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Participant must agree to all protocol required contraception requirements",
                        "criterion": "contraception requirements",
                        "requirement": {
                            "requirement_type": "agreement",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "avoid sperm or egg donations or freezing for future reproductive use while on study and for 90 days (males) or 6 months (females) after the last dose of study treatment",
                                "criterion": "sperm or egg donation or freezing for future reproductive use",
                                "requirement": {
                                    "requirement_type": "avoidance",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "avoid sperm or egg donations or freezing for future reproductive use while on study and for 90 days (males) or 6 months (females) after the last dose of study treatment",
                                "criterion": "sperm or egg donation or freezing for future reproductive use",
                                "requirement": {
                                    "requirement_type": "duration (males)",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 90,
                                        "unit": "days"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "avoid sperm or egg donations or freezing for future reproductive use while on study and for 90 days (males) or 6 months (females) after the last dose of study treatment",
                                "criterion": "sperm or egg donation or freezing for future reproductive use",
                                "requirement": {
                                    "requirement_type": "duration (females)",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 12 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 12 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 12 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Pretreatment clinical laboratory values meeting the following criteria: (a) Hematology: white blood cell (WBC) count less than or equal to (<=) 20*10^9/liter (L) and (b) renal function; Estimated or measured glomerular filtration rate greater than or equal to (>=) 50 milliliter per minute (mL/min) per four variable modified diet in renal disease (MDRD) equation",
                "criterions": [
                    {
                        "exact_snippets": "white blood cell (WBC) count less than or equal to (<=) 20*10^9/liter (L)",
                        "criterion": "white blood cell (WBC) count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 20,
                                "unit": "10^9/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Estimated or measured glomerular filtration rate greater than or equal to (>=) 50 milliliter per minute (mL/min) per four variable modified diet in renal disease (MDRD) equation",
                        "criterion": "glomerular filtration rate (GFR)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "white blood cell (WBC) count less than or equal to (<=) 20*10^9/liter (L)",
                        "criterion": "white blood cell (WBC) count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 20,
                                "unit": "10^9/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Estimated or measured glomerular filtration rate greater than or equal to (>=) 50 milliliter per minute (mL/min) per four variable modified diet in renal disease (MDRD) equation",
                        "criterion": "glomerular filtration rate (GFR)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participants greater than 18 years are eligible",
                "criterions": [
                    {
                        "exact_snippets": "Participants greater than 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Participants greater than 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participants greater than or equal (>=)12 and less than (<) 18 years of age are only eligible for the Phase 1 adolescent cohort",
                "criterions": [
                    {
                        "exact_snippets": "greater than or equal (>=)12 and less than (<) 18 years of age",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "age range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 12,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 18,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "greater than or equal (>=)12 and less than (<) 18 years of age",
                    "criterion": "age",
                    "requirement": {
                        "requirement_type": "age range",
                        "expected_value": {
                            "comparisons": [
                                {
                                    "operator": ">=",
                                    "value": 12,
                                    "unit": "years"
                                },
                                {
                                    "operator": "<",
                                    "value": 18,
                                    "unit": "years"
                                }
                            ]
                        }
                    }
                },
                "then_criteria": null,
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* Acute leukemia harboring histone-lysine N-methyltransferase 2A (KMT2A), nucleophosmin 1 gene (NPM1) or nucleoporin 98 gene or nucleoporin 214 gene (NUP98 or NUP214) alterations",
                "criterions": [
                    {
                        "exact_snippets": "Acute leukemia",
                        "criterion": "acute leukemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "harboring histone-lysine N-methyltransferase 2A (KMT2A) ... alterations",
                        "criterion": "KMT2A gene alteration",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "harboring ... nucleophosmin 1 gene (NPM1) ... alterations",
                        "criterion": "NPM1 gene alteration",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "harboring ... nucleoporin 98 gene ... alterations",
                        "criterion": "NUP98 gene alteration",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "harboring ... nucleoporin 214 gene (NUP214) alterations",
                        "criterion": "NUP214 gene alteration",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Acute leukemia",
                        "criterion": "acute leukemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "harboring histone-lysine N-methyltransferase 2A (KMT2A) ... alterations",
                                "criterion": "KMT2A gene alteration",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "harboring ... nucleophosmin 1 gene (NPM1) ... alterations",
                                "criterion": "NPM1 gene alteration",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "or_criteria": [
                                    {
                                        "exact_snippets": "harboring ... nucleoporin 98 gene ... alterations",
                                        "criterion": "NUP98 gene alteration",
                                        "requirement": {
                                            "requirement_type": "presence",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "harboring ... nucleoporin 214 gene (NUP214) alterations",
                                        "criterion": "NUP214 gene alteration",
                                        "requirement": {
                                            "requirement_type": "presence",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Phase 1:",
                "criterions": [
                    {
                        "exact_snippets": "Phase 1:",
                        "criterion": "trial phase",
                        "requirement": {
                            "requirement_type": "phase",
                            "expected_value": "1"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Phase 1:",
                        "criterion": "trial phase",
                        "requirement": {
                            "requirement_type": "phase",
                            "expected_value": "1"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Phase: 2",
                "criterions": [
                    {
                        "exact_snippets": "Phase: 2",
                        "criterion": "trial phase",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "2"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Phase: 2",
                        "criterion": "trial phase",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "2"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "For Both Phase 1 and 2:",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "* AML harboring KMT2A-r (gene rearrangement/translocation) or NPM1 mutations only",
                "criterions": [
                    {
                        "exact_snippets": "AML harboring KMT2A-r (gene rearrangement/translocation) or NPM1 mutations only",
                        "criterion": "acute myeloid leukemia (AML)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "AML harboring KMT2A-r (gene rearrangement/translocation)",
                        "criterion": "KMT2A gene rearrangement/translocation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "AML harboring ... NPM1 mutations only",
                        "criterion": "NPM1 mutation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "AML harboring KMT2A-r (gene rearrangement/translocation) or NPM1 mutations only",
                        "criterion": "acute myeloid leukemia (AML)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "AML harboring KMT2A-r (gene rearrangement/translocation)",
                                "criterion": "KMT2A gene rearrangement/translocation",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "AML harboring ... NPM1 mutations only",
                                "criterion": "NPM1 mutation",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* Exclusion criteria related to stem cell transplant: a. Received prior treatment with allogenic bone marrow or stem cell transplant <=3 months before the first dose of study treatment; b. Has evidence of graft versus host disease; c. Received donor lymphocyte infusion <=1 month before the first dose of study treatment; d. Requires immunosuppressant therapy (exception: daily doses <=10 milligrams (mg) prednisone or equivalent are allowed for adrenal replacement)",
                "criterions": [
                    {
                        "exact_snippets": "Received prior treatment with allogenic bone marrow or stem cell transplant <=3 months before the first dose of study treatment",
                        "criterion": "prior allogenic bone marrow or stem cell transplant",
                        "requirement": {
                            "requirement_type": "time since transplant",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Has evidence of graft versus host disease",
                        "criterion": "graft versus host disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Received donor lymphocyte infusion <=1 month before the first dose of study treatment",
                        "criterion": "donor lymphocyte infusion",
                        "requirement": {
                            "requirement_type": "time since infusion",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Requires immunosuppressant therapy (exception: daily doses <=10 milligrams (mg) prednisone or equivalent are allowed for adrenal replacement)",
                        "criterion": "immunosuppressant therapy",
                        "requirement": {
                            "requirement_type": "requirement",
                            "expected_value": "requires immunosuppressant therapy"
                        }
                    },
                    {
                        "exact_snippets": "Requires immunosuppressant therapy (exception: daily doses <=10 milligrams (mg) prednisone or equivalent are allowed for adrenal replacement)",
                        "criterion": "immunosuppressant therapy",
                        "requirement": {
                            "requirement_type": "exception",
                            "expected_value": "daily doses <=10 milligrams (mg) prednisone or equivalent are allowed for adrenal replacement"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Received prior treatment with allogenic bone marrow or stem cell transplant <=3 months before the first dose of study treatment",
                        "criterion": "prior allogenic bone marrow or stem cell transplant",
                        "requirement": {
                            "requirement_type": "time since transplant",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Has evidence of graft versus host disease",
                        "criterion": "graft versus host disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Received donor lymphocyte infusion <=1 month before the first dose of study treatment",
                        "criterion": "donor lymphocyte infusion",
                        "requirement": {
                            "requirement_type": "time since infusion",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Requires immunosuppressant therapy (exception: daily doses <=10 milligrams (mg) prednisone or equivalent are allowed for adrenal replacement)",
                                "criterion": "immunosuppressant therapy",
                                "requirement": {
                                    "requirement_type": "requirement",
                                    "expected_value": "requires immunosuppressant therapy"
                                }
                            },
                            {
                                "not_criteria": {
                                    "exact_snippets": "Requires immunosuppressant therapy (exception: daily doses <=10 milligrams (mg) prednisone or equivalent are allowed for adrenal replacement)",
                                    "criterion": "immunosuppressant therapy",
                                    "requirement": {
                                        "requirement_type": "exception",
                                        "expected_value": "daily doses <=10 milligrams (mg) prednisone or equivalent are allowed for adrenal replacement"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Active central nervous system (CNS) disease",
                "criterions": [
                    {
                        "exact_snippets": "Active central nervous system (CNS) disease",
                        "criterion": "central nervous system (CNS) disease",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Active central nervous system (CNS) disease",
                    "criterion": "central nervous system (CNS) disease",
                    "requirement": {
                        "requirement_type": "activity status",
                        "expected_value": "active"
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Prior cancer immunotherapy within 4 weeks prior to enrollment or blinatumomab within 2 weeks prior to enrollment. Additional prior cancer therapies must not be given within 4 weeks prior to enrollment or 5 half-lives of the agent (whichever is shorter)",
                "criterions": [
                    {
                        "exact_snippets": "Prior cancer immunotherapy within 4 weeks prior to enrollment",
                        "criterion": "prior cancer immunotherapy",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "blinatumomab within 2 weeks prior to enrollment",
                        "criterion": "prior blinatumomab therapy",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Additional prior cancer therapies must not be given within 4 weeks prior to enrollment or 5 half-lives of the agent (whichever is shorter)",
                        "criterion": "additional prior cancer therapies",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": "greater than or equal to 4 weeks or 5 half-lives of the agent, whichever is shorter"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "Prior cancer immunotherapy within 4 weeks prior to enrollment",
                            "criterion": "prior cancer immunotherapy",
                            "requirement": {
                                "requirement_type": "time since last treatment",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 4,
                                    "unit": "weeks"
                                }
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "blinatumomab within 2 weeks prior to enrollment",
                            "criterion": "prior blinatumomab therapy",
                            "requirement": {
                                "requirement_type": "time since last treatment",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 2,
                                    "unit": "weeks"
                                }
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "Additional prior cancer therapies must not be given within 4 weeks prior to enrollment or 5 half-lives of the agent (whichever is shorter)",
                            "criterion": "additional prior cancer therapies",
                            "requirement": {
                                "requirement_type": "time since last treatment",
                                "expected_value": "greater than or equal to 4 weeks or 5 half-lives of the agent, whichever is shorter"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Acute promyelocytic leukemia, diagnosis of Down syndrome associated leukemia or juvenile myelomonocytic leukemia according to World Health Organization (WHO) 2016 criteria",
                "criterions": [
                    {
                        "exact_snippets": "Acute promyelocytic leukemia",
                        "criterion": "acute promyelocytic leukemia",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "diagnosis of Down syndrome associated leukemia",
                        "criterion": "Down syndrome associated leukemia",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "juvenile myelomonocytic leukemia according to World Health Organization (WHO) 2016 criteria",
                        "criterion": "juvenile myelomonocytic leukemia",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "juvenile myelomonocytic leukemia according to World Health Organization (WHO) 2016 criteria",
                        "criterion": "juvenile myelomonocytic leukemia",
                        "requirement": {
                            "requirement_type": "diagnostic criteria",
                            "expected_value": "World Health Organization (WHO) 2016 criteria"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Acute promyelocytic leukemia",
                        "criterion": "acute promyelocytic leukemia",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "diagnosis of Down syndrome associated leukemia",
                        "criterion": "Down syndrome associated leukemia",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "juvenile myelomonocytic leukemia according to World Health Organization (WHO) 2016 criteria",
                                "criterion": "juvenile myelomonocytic leukemia",
                                "requirement": {
                                    "requirement_type": "diagnosis",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "juvenile myelomonocytic leukemia according to World Health Organization (WHO) 2016 criteria",
                                "criterion": "juvenile myelomonocytic leukemia",
                                "requirement": {
                                    "requirement_type": "diagnostic criteria",
                                    "expected_value": "World Health Organization (WHO) 2016 criteria"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Prior solid organ transplantation",
                "criterions": [
                    {
                        "exact_snippets": "Prior solid organ transplantation",
                        "criterion": "solid organ transplantation",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Prior solid organ transplantation",
                    "criterion": "solid organ transplantation",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                }
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Must have had an initial diagnosis of acute myeloid leukemia (AML) per the WHO 2022 classification criteria and have relapsed/refractory disease",
                "criterions": [
                    {
                        "exact_snippets": "initial diagnosis of acute myeloid leukemia (AML) per the WHO 2022 classification criteria",
                        "criterion": "acute myeloid leukemia (AML) diagnosis",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "initial diagnosis of acute myeloid leukemia (AML) per the WHO 2022 classification criteria",
                        "criterion": "acute myeloid leukemia (AML) diagnosis",
                        "requirement": {
                            "requirement_type": "classification system",
                            "expected_value": "WHO 2022"
                        }
                    },
                    {
                        "exact_snippets": "have relapsed/refractory disease",
                        "criterion": "disease status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* A female of childbearing potential must have a negative highly sensitive serum beta-human chorionic gonadotropin at screening and within 48 hours prior to the first dose of study treatment",
                "criterions": [
                    {
                        "exact_snippets": "A female of childbearing potential",
                        "criterion": "sex and reproductive status",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "A female of childbearing potential",
                        "criterion": "sex and reproductive status",
                        "requirement": {
                            "requirement_type": "reproductive status",
                            "expected_value": "of childbearing potential"
                        }
                    },
                    {
                        "exact_snippets": "must have a negative highly sensitive serum beta-human chorionic gonadotropin at screening and within 48 hours prior to the first dose of study treatment",
                        "criterion": "serum beta-human chorionic gonadotropin (β-hCG)",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "must have a negative highly sensitive serum beta-human chorionic gonadotropin at screening and within 48 hours prior to the first dose of study treatment",
                        "criterion": "serum beta-human chorionic gonadotropin (β-hCG)",
                        "requirement": {
                            "requirement_type": "test type",
                            "expected_value": "highly sensitive serum β-hCG"
                        }
                    },
                    {
                        "exact_snippets": "must have a negative highly sensitive serum beta-human chorionic gonadotropin at screening and within 48 hours prior to the first dose of study treatment",
                        "criterion": "serum beta-human chorionic gonadotropin (β-hCG)",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": [
                                "at screening",
                                "within 48 hours prior to the first dose of study treatment"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Relapsed or refractory (R/R) acute leukemia and has exhausted, or is ineligible for, available therapeutic options",
                "criterions": [
                    {
                        "exact_snippets": "Relapsed or refractory (R/R) acute leukemia",
                        "criterion": "acute leukemia",
                        "requirement": {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "has exhausted, or is ineligible for, available therapeutic options",
                        "criterion": "therapeutic options",
                        "requirement": {
                            "requirement_type": "exhausted or ineligible",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Eastern Cooperative Oncology Group (ECOG) performance status grade of 0, 1 or 2. Adolescent participants only: Performance status >=70 by Lansky scale (for participants less than [<]16 years of age) or >=70 Karnofsky scale (for participants >=16 years of age)",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status grade of 0, 1 or 2",
                        "criterion": "ECOG performance status grade",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": [
                                "0",
                                "1",
                                "2"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Adolescent participants only: Performance status >=70 by Lansky scale (for participants less than [<]16 years of age)",
                        "criterion": "Lansky performance status score",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "N/A"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Adolescent participants only: Performance status >=70 by Lansky scale (for participants less than [<]16 years of age)",
                        "criterion": "Lansky performance status score",
                        "requirement": {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": "<",
                                "value": 16,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Adolescent participants only: ... >=70 Karnofsky scale (for participants >=16 years of age)",
                        "criterion": "Karnofsky performance status score",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "N/A"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Adolescent participants only: ... >=70 Karnofsky scale (for participants >=16 years of age)",
                        "criterion": "Karnofsky performance status score",
                        "requirement": {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 16,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "* QTc according to Fridericia's formula (QTcF) for males >= 450 millisecond (msec) or for females >= 470 msec. Participants with a family history of Long QT syndrome are excluded",
                "criterions": [
                    {
                        "exact_snippets": "QTc according to Fridericia's formula (QTcF) for males >= 450 millisecond (msec)",
                        "criterion": "QTcF (Fridericia's formula) in males",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 450,
                                "unit": "msec"
                            }
                        }
                    },
                    {
                        "exact_snippets": "QTc according to Fridericia's formula (QTcF) ... for females >= 470 msec",
                        "criterion": "QTcF (Fridericia's formula) in females",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 470,
                                "unit": "msec"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Participants with a family history of Long QT syndrome are excluded",
                        "criterion": "family history of Long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "QTc according to Fridericia's formula (QTcF) for males >= 450 millisecond (msec)",
                                "criterion": "QTcF (Fridericia's formula) in males",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 450,
                                        "unit": "msec"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "QTc according to Fridericia's formula (QTcF) ... for females >= 470 msec",
                                "criterion": "QTcF (Fridericia's formula) in females",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 470,
                                        "unit": "msec"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "Participants with a family history of Long QT syndrome are excluded",
                        "criterion": "family history of Long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "failed_miscellaneous": []
}